Does tofu cause gynaecomastia? It is a question increasingly asked by men who consume soya-based foods and notice changes in breast tissue. Tofu contains isoflavones — plant compounds with a weak oestrogen-like structure — which has fuelled concern about hormonal disruption in males. However, the clinical evidence tells a largely reassuring story. This article examines the science behind phytoestrogens, reviews what UK and international guidance says, explores the well-established causes of gynaecomastia, and explains when breast tissue changes in males warrant a GP assessment.

What Is Gynaecomastia and What Causes It?

Gynaecomastia is benign glandular breast tissue enlargement in males caused by an imbalance between oestrogen and androgen activity. Established causes include medications, obesity, hypogonadism, liver disease, and physiological changes at puberty or with ageing.

Gynaecomastia is the benign enlargement of glandular breast tissue in males, affecting one or both breasts. It is distinct from pseudogynaecomastia, which refers to fat deposition in the chest area without true glandular growth — a distinction that is clinically important, as the two conditions have different causes and management pathways. Gynaecomastia is common: it is estimated to affect a substantial proportion of adolescent boys during puberty and is also frequently seen in older men, particularly those aged 50 to 80, though prevalence figures vary across studies.

The underlying mechanism involves an imbalance between oestrogen and androgen activity in breast tissue. Oestrogens stimulate ductal growth, whilst androgens — primarily testosterone — counteract this effect. When this balance tips in favour of oestrogen, either through increased oestrogen levels, reduced androgen levels, or altered receptor sensitivity, glandular breast tissue can proliferate.

Established causes of gynaecomastia include:

• Physiological changes — puberty, ageing, and the neonatal period

• Obesity — excess adipose tissue increases peripheral aromatisation of androgens to oestrogens and can cause or worsen gynaecomastia; it also contributes to pseudogynaecomastia

• Medications — including spironolactone, finasteride and dutasteride (5-alpha-reductase inhibitors), bicalutamide and cyproterone (antiandrogens), cimetidine, anabolic steroids, some antipsychotics (e.g., risperidone, haloperidol), ketoconazole, GnRH analogues, and certain antiretrovirals (e.g., efavirenz)

• Medical conditions — such as hypogonadism (including Klinefelter syndrome), hyperthyroidism, liver cirrhosis, chronic kidney disease, and testicular or adrenal tumours

• Substance use — alcohol and opioids (including methadone) are well-recognised contributors; an association with cannabis has been reported, though causality remains uncertain

In many cases, no clear cause is identified, and the condition is labelled idiopathic. Understanding the hormonal basis of gynaecomastia is important when evaluating whether dietary factors — such as soya consumption — could plausibly contribute to its development. Further information is available from the NHS conditions page on gynaecomastia and NICE Clinical Knowledge Summary (CKS) on gynaecomastia.

Phytoestrogens in Tofu and How They Work in the Body

Tofu contains isoflavones that bind preferentially to oestrogen receptor beta with much lower affinity than endogenous oestradiol, acting as weak partial agonists or antagonists. At typical dietary doses, their oestrogenic effect is unlikely to be clinically significant in healthy individuals.

Tofu is made from soya bean curd and is a rich source of isoflavones, a class of phytoestrogens — naturally occurring plant compounds with a chemical structure loosely similar to human oestradiol. The primary isoflavones in soya are genistein and daidzein. Because of their structural resemblance to oestrogen, there has been longstanding public concern about whether consuming soya products like tofu could disrupt hormonal balance in males.

However, it is important to understand how phytoestrogens actually behave in the body. Unlike synthetic oestrogens or endogenous oestradiol, isoflavones have preferential binding to the beta subtype of the oestrogen receptor (ERβ) with considerably lower affinity than endogenous oestrogen. Depending on the tissue and hormonal environment, they can act as weak partial agonists or antagonists — a profile sometimes described as SERM-like (selective oestrogen receptor modulator-like), though they are not true SERMs in the pharmacological sense.

Key points about soya isoflavones and human physiology:

• Their bioavailability varies significantly between individuals, influenced by gut microbiome composition

• They are metabolised into compounds such as equol, which has greater oestrogenic activity — but population studies suggest that only a proportion of people produce equol efficiently, with variability across different populations

• At typical dietary doses, their oestrogenic potency is estimated to be substantially weaker than endogenous oestradiol, though the precise magnitude depends on the tissue and endpoint studied

This pharmacological profile suggests that, in most healthy individuals consuming tofu as part of a balanced diet, the oestrogenic effect of isoflavones is unlikely to be clinically significant. The European Food Safety Authority (EFSA) 2015 scientific opinion on isoflavones and the British Dietetic Association (BDA) Food Fact Sheet on soya and health both provide useful context on these mechanisms. Nevertheless, the theoretical mechanism has fuelled ongoing research and public debate.

What the Clinical Evidence Says About Soya and Gynaecomastia

Clinical trials and meta-analyses consistently show that moderate soya consumption does not significantly alter male reproductive hormone levels or cause gynaecomastia. Only exceptional case reports involving extremely high isoflavone intakes suggest any possible risk.

The question of whether tofu or soya products cause gynaecomastia in males has been examined in clinical studies, though the overall body of evidence remains limited and largely reassuring. The majority of well-designed clinical trials and systematic reviews have found that normal dietary consumption of soya does not significantly alter reproductive hormone levels in men, including testosterone, oestradiol, or sex hormone-binding globulin (SHBG).

A 2010 meta-analysis published in Fertility and Sterility (Hamilton-Reeves et al.) reviewed 15 placebo-controlled studies and concluded that neither soya foods nor isoflavone supplements had a significant effect on testosterone concentrations in men. A 2021 systematic review and meta-analysis (Reed et al., Reproductive Toxicology) similarly found no consistent evidence linking soya intake to changes in circulating oestrogen levels or clinical signs of feminisation in males.

There are, however, a small number of published case reports describing gynaecomastia or other feminising effects in men consuming very large quantities of soya — for example, several litres of soya milk daily, equating to isoflavone intakes far exceeding those achievable through typical dietary consumption (which is generally in the range of 25–50 mg of isoflavones per day from one to two servings of tofu). These cases are considered exceptional and are not representative of standard tofu consumption. It is also worth noting that case reports represent the lowest level of clinical evidence and cannot establish causation.

In summary:

• Moderate soya consumption (e.g., one to two servings of tofu per day, providing approximately 25–50 mg of isoflavones) is not supported by current evidence as a cause of gynaecomastia

• Extremely high isoflavone intake may theoretically carry a small risk, though this is poorly evidenced and based on exceptional case reports

• There is no official link recognised by UK regulatory or clinical bodies between standard tofu consumption and gynaecomastia

Individuals with concerns about soya intake and hormonal health should seek personalised advice from a GP or registered dietitian.

NHS and NICE Guidance on Dietary Oestrogens

Neither the NHS, NICE, nor the UK Food Standards Agency has issued guidance warning against tofu or soya consumption in relation to gynaecomastia in healthy males. Soya foods are broadly recognised as a nutritious component of a balanced diet.

Neither the NHS nor NICE has issued specific guidance warning against soya or tofu consumption in relation to gynaecomastia in otherwise healthy males. The NHS broadly recognises soya-based foods as a nutritious component of a balanced diet, particularly within vegetarian and vegan eating patterns. Tofu is frequently highlighted as a valuable source of plant-based protein, calcium, and iron.

The EFSA concluded in its 2015 scientific opinion that isoflavones from food sources do not adversely affect breast, thyroid, or uterine tissue in postmenopausal women at typical dietary intakes. Whilst this assessment focused on women, there is no specific guidance from UK or European regulatory bodies suggesting harm to male hormonal health from dietary soya at normal intake levels. The UK Food Standards Agency (FSA) has not identified dietary soya as a risk factor for hormonal disruption in healthy adults.

For individuals taking medications that affect oestrogen or androgen pathways — such as hormone therapies, antiandrogens, or certain psychiatric medications — it may be worth discussing dietary habits with a healthcare professional. However, no clinically significant interactions between normal dietary soya intake and these medicines are currently established; any review should be individualised rather than based on a general precaution. Similarly, men with pre-existing conditions affecting hormone metabolism (e.g., liver disease or hypogonadism) may wish to seek tailored dietary advice.

In the absence of NICE-specific guidance on this topic, clinicians are advised to follow a patient-centred approach: taking a thorough dietary and medication history, investigating identifiable hormonal causes, and avoiding unnecessary dietary restriction unless there is a clear clinical rationale. Patients should be reassured that tofu, consumed as part of a varied diet, is not considered a recognised risk factor for gynaecomastia by UK health authorities.

Other Common Causes of Gynaecomastia to Consider

Medications — including spironolactone, finasteride, anabolic steroids, and certain antipsychotics — are among the most common causes of gynaecomastia in adults. Obesity, alcohol, hypogonadism, liver cirrhosis, and testicular tumours must also be excluded before attributing symptoms to diet.

When evaluating breast tissue changes in males, it is clinically important to consider the full range of potential causes before attributing symptoms to dietary factors such as tofu. In the majority of cases, gynaecomastia has a physiological, pharmacological, or pathological explanation that warrants proper investigation.

Medications are one of the most common causes of gynaecomastia in adults. Drugs associated with gynaecomastia include (as listed in the BNF and relevant SmPCs):

• Spironolactone and other anti-androgens (e.g., bicalutamide, cyproterone)

• 5-alpha-reductase inhibitors — finasteride and dutasteride, used for benign prostatic hyperplasia and male-pattern hair loss

• Anabolic steroids and testosterone replacement therapy (paradoxically, through aromatisation to oestradiol)

• Cimetidine (H2-receptor antagonist) — a well-established association; proton pump inhibitors have been reported in some cases but the evidence is considerably weaker

• Some antipsychotics (e.g., haloperidol, risperidone) via hyperprolactinaemia

• Ketoconazole and GnRH analogues (e.g., goserelin, leuprorelin)

• Certain antiretrovirals — efavirenz in particular has been associated with gynaecomastia

• Digoxin and certain calcium channel blockers

If a patient is taking any of these medicines and develops gynaecomastia, this should be discussed with their prescriber. Suspected adverse drug reactions, including drug-induced gynaecomastia, can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Recreational substances including alcohol and opioids (e.g., methadone, heroin) are well-documented contributors. An association with cannabis has been reported in some studies, though causality has not been firmly established.

Obesity is an important and often overlooked contributor: excess adipose tissue increases peripheral conversion of androgens to oestrogens and may cause or exacerbate gynaecomastia.

Underlying medical conditions should always be excluded, particularly:

• Hypogonadism — primary (e.g., Klinefelter syndrome) or secondary

• Hyperthyroidism — elevated thyroid hormones can increase SHBG and reduce free testosterone

• Liver cirrhosis — impairs oestrogen metabolism

• Testicular tumours — some secrete human chorionic gonadotrophin (hCG), stimulating oestrogen production

• Adrenal tumours producing oestrogen precursors

A thorough clinical history, physical examination, and targeted blood tests are essential first steps. Investigations should include LH, FSH, testosterone, oestradiol, prolactin, beta-hCG, thyroid function, and liver function tests. Testicular ultrasound should be considered if a testicular tumour is suspected. Further guidance on assessment and investigation is available from NICE CKS: Gynaecomastia. Attributing gynaecomastia to tofu without excluding these causes would be clinically premature.

When to Speak to a GP About Breast Tissue Changes

Any male with a new firm breast lump, unilateral swelling, nipple discharge, or skin changes should see a GP promptly to exclude male breast cancer. NICE NG12 sets out urgent two-week-wait referral criteria for unexplained breast changes in males.

Any male who notices changes in breast tissue — including swelling, tenderness, a firm lump beneath the nipple, or nipple discharge — should seek a GP assessment promptly. Whilst gynaecomastia is most often benign, it is important to rule out more serious conditions, including male breast cancer, which, although rare, accounts for approximately 1% of all breast cancer diagnoses in the UK.

Seek a GP appointment if you notice:

• A new, firm, or hard lump in one or both breasts

• Unilateral (one-sided) breast swelling, particularly if asymmetrical

• Nipple discharge, especially if bloodstained

• Skin changes over the breast, such as dimpling or puckering

• Breast changes accompanied by unexplained weight loss, fatigue, or testicular changes

NICE NG12 (Suspected Cancer: Recognition and Referral) sets out urgent referral criteria relevant to breast changes in males. GPs should consider an urgent referral (two-week wait) to a specialist breast clinic for males aged 30 and over with an unexplained breast lump, and for males aged 50 and over with unilateral nipple changes (such as discharge, retraction, or other nipple abnormality). These criteria exist to ensure timely assessment and should not cause alarm — the majority of referrals do not result in a cancer diagnosis.

For adolescent boys experiencing breast changes during puberty, reassurance is often appropriate, as physiological gynaecomastia typically resolves within six to 24 months. However, if changes persist beyond two years or into late puberty, or if they are causing significant pain or psychological distress, a GP referral to a paediatric endocrinologist or surgeon may be warranted.

In adults, the GP will typically take a full medication and lifestyle history — including dietary habits, supplement use, alcohol intake, and weight — and arrange relevant blood tests. A medication review is an important part of this assessment, as stopping or switching an implicated drug may resolve the condition. Addressing modifiable factors such as excess weight and alcohol use may also be beneficial. If a hormonal imbalance or underlying condition is identified, targeted treatment can be initiated.

In cases where gynaecomastia is persistent and causing significant distress, referral for surgical assessment (subcutaneous mastectomy) may be considered; however, access to surgery on the NHS varies according to local Integrated Care Board (ICB) commissioning policies, and eligibility criteria differ between areas.

Patients concerned about soya or tofu consumption should feel comfortable raising this with their GP. A clinician can help contextualise dietary factors within the broader clinical picture and provide evidence-based reassurance or further investigation as appropriate.

Have questions about your medication? Our pharmacists are here to help →

Frequently Asked Questions